Aurobindo Pharma Limited — JV/Acquisition, 26-09-2025: Acquisition

Aurobindo Pharma shared an update on an internal restructuring involving 100% shares of CuraTeQ Biologics s.r.o. The transfer of these shares between its wholly-owned subsidiaries, from Helix Healthcare B.V. to Curateq Biologics B.V., is now expected to finalize by November 30, 2025. This internal re-alignment supports Aurobindo's ongoing focus and optimization within its biologics segment. The move is an administrative step to streamline its existing operations rather than a new external acquisition.